reverepharma.comAbout company
Revere Pharmaceuticals is an oncology-focused biotechnology company leading the development of small molecule therapeutics targeting Rac1 signaling for cancers with unmet clinical needs. Rac1 activity is a key driver of metastatic progression and drug resistance in diverse cancer types. Revere’s lead Rac1 targeted drug candidate is REV-440. The successful development of REV-440 has the potential to provide meaningful clinical impact in multiple refractory cancers characterized by aberrant Rac1 signaling. Revere expects REV-440 to enter clinical trials in 2021. Initial clinical development of REV-440 will focus on recurrent ovarian cancer and the critical unmet clinical need of platinum-resistant disease. Treatment of ovarian cancer with REV-440 is supported by compelling preclinical efficacy data. The company was founded in 2016.
